iSERA Lifesciences Completes Strategic Pivot with ₹78 Cr iSERA Biological Acquisition

iSERA Lifesciences Limited has approved the acquisition of iSERA Biological Limited for ₹78.00 crore via a share swap. iSERA Biological reported a turnover of ₹18.36 crore in FY24-25.

Reader Takeaway: Pharma expansion drives growth; deal hinges on final approvals.

What just happened (today’s filing)

The board of iSERA Lifesciences Limited, formerly Covidh Technologies Ltd., met on April 21, 2026, approving the acquisition of up to 100% of iSERA Biological Limited.

The transaction will be executed through a share swap, with a total consideration of ₹78.00 crore. This involves issuing 1,61,82,800 iSERA Lifesciences shares at ₹48.20 per share on a 1:1 swap ratio.

Additionally, the company approved an increase in its authorized share capital from ₹11.00 crore to ₹25.00 crore and enhanced investment/loan limits to ₹1,000 crore.

New Memorandum and Articles of Association were also adopted, reflecting the company's evolving business focus.

Why this matters

This acquisition signifies a major strategic consolidation for iSERA Lifesciences, marking a decisive shift towards the life sciences and pharmaceutical sector. It aims to leverage synergies and expand its market presence.

The move is critical for iSERA Lifesciences as it transitions from its IT/ITES background to become a prominent player in a high-growth industry.

The backstory (grounded)

Covdh Technologies Limited, established in 1993, was primarily an IT and IT-enabled services provider. In April 2026, the company officially rebranded to iSERA Lifesciences Limited, signalling its strategic pivot.

Prior to this board approval, the company had executed a non-binding Letter of Intent (LOI) in February 2026 to acquire iSERA Biological Private Limited, a biotech firm focused on biopharmaceuticals.

What changes now

• Upon completion, iSERA Biological Limited will become a Wholly Owned Subsidiary of iSERA Lifesciences Limited.
• The company's business focus will significantly shift towards expanding and consolidating its presence in the pharmaceutical and life sciences sector.
• Increased authorized share capital provides greater financial flexibility for future growth and capital needs.
• Enhanced investment and loan limits allow for more substantial strategic initiatives.

Risks to watch

The acquisition is subject to receiving necessary approvals, including member approval via Postal Ballot/Remote E-Voting and in-principle approval from BSE Limited.

Peer comparison

iSERA Lifesciences is now entering a competitive landscape alongside established pharmaceutical giants such as Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Cipla Ltd., and Dr. Reddy's Laboratories Ltd.. These peers represent the growth potential and market dynamics of the Indian pharmaceutical sector, which is poised for significant expansion.

Context metrics (time-bound)

• iSERA Biological's turnover stood at ₹18.36 crore for the financial year FY24–FY25.
• The company's authorized share capital has been increased from ₹11.00 crore to ₹25.00 crore as of April 21, 2026.
• Investment and loan limits have been enhanced to ₹1,000 crore.

What to track next

• Monitor the outcome of the member approval process via Postal Ballot / Remote E-Voting.
• Track the receipt of the in-principle approval from BSE Limited.
• Observe the completion timeline of the share swap transaction, which is expected within 15 days of final approvals.
• Assess the integration progress and synergy realization post-acquisition.